Table 1.
Composition of diacerein loaded proliposomes of egg lecithin and soy lecithin.
Table 2.
Evaluation of different parameters of proliposomal formulations.
Fig 1.
Scanning electron microscopic images of D5PL (A, B) and D11PL (C, D) and transmission electron microscopic images of D5PL (E) and D11PL (F).
Fig 2.
FTIR analysis of diacerein (A), egg lecithin based physical mixture (B), soy lecithin based physical mixture (C), D5PL (D) and D11PL (E).
Fig 3.
Powder x-ray diffractogram of diacerein (A), egg lecithin based physical mixture (B), soy lecithin based physical mixture (C), D5PL (D) and D11PL (E).
Fig 4.
DSC of diacerein (A), egg lecithin based physical mixture (B), soy lecithin based physical mixture (C), D5PL (D) and D11PL (E).
Fig 5.
Comparison of drug release profile of PL formulations: A (D1PL-D6PL and drug), and B (D7PL-D12PL and drug).
Table 3.
Kinetic modeling of drug release profile of PL formulations.
Fig 6.
Ex vivo permeation analysis of control gel and liposomal gels (D5PL-G and D11PL-G).
Table 4.
Permeation analysis of Liposomal gel.
Fig 7.
Histopathological microscopic examination of different tissues of Wistar rats of group-I (control), group-II (test) and group-III (test).
Table 5.
Biochemical analysis of Wistar rats.